Thompson H S, Davies M L, Watts M J, Mann A E, Holding F P, O'Neill T, Beech J T, Thompson S J, Leesman G D, Ulrich J T
Cantab Pharmaceuticals Research Ltd, Cambridge, UK.
Vaccine. 1998 Dec;16(20):1993-9. doi: 10.1016/s0264-410x(98)00088-7.
The regression of genital warts is believed to be a T-cell-mediated immune effect. We have sought to enhance the immunogenicity of a therapeutic vaccine for the treatment of genital warts with the use of the adjuvant monophosphoryl lipid A (MPL-immunostimulant), a detoxified form of the lipopolysaccharide (LPS) of Salmonella minnesota R595. The comparative immunogenicity and reactogenicity of a recombinant human papillomavirus type 6 (HPV6) L2E7 fusion protein in either aqueous, oil-in-water emulsions or Alhydrogel formulations containing MPL was evaluated. We conclude that the simple addition of MPL to the L2E7 fusion protein already adsorbed onto Alhydrogel preferentially enhances antigen specific in vitro T-cell proliferative responses, IFN gamma production and in vivo delayed type hypersensitivity responses without increasing its reactogenicity.
尖锐湿疣的消退被认为是一种T细胞介导的免疫效应。我们试图通过使用单磷酰脂质A（MPL免疫刺激剂）来增强治疗尖锐湿疣的治疗性疫苗的免疫原性，MPL是明尼苏达沙门氏菌R595脂多糖（LPS）的一种解毒形式。评估了重组人乳头瘤病毒6型（HPV6）L2E7融合蛋白在水性、水包油乳液或含MPL的氢氧化铝凝胶制剂中的比较免疫原性和反应原性。我们得出结论，在已经吸附到氢氧化铝凝胶上的L2E7融合蛋白中简单添加MPL，优先增强了抗原特异性的体外T细胞增殖反应、γ干扰素产生和体内迟发型超敏反应，而不会增加其反应原性。
